Rebimastat
- Generic Name
- Rebimastat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H41N5O5S
- CAS Number
- 259188-38-0
- Unique Ingredient Identifier
- 1B47R6ZX4K
- Indication
Investigated for use/treatment in lung cancer and prostate cancer.
- Associated Conditions
- -
- Associated Therapies
- -
BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma
- First Posted Date
- 2003-08-05
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 59
- Registration Number
- NCT00024024
- Locations
- 🇺🇸
Herbert Irving Comprehensive Cancer Center, New York, New York, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer
Phase 2
Completed
- Conditions
- Adenocarcinoma of the ProstateRecurrent Prostate CancerStage IV Prostate Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00039104
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
Phase 2
Completed
- Conditions
- Adenocarcinoma of the ProstateBone MetastasesHormone-resistant Prostate CancerRecurrent Prostate CancerStage IV Prostate Cancer
- Interventions
- Drug: rebimastatOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 68
- Registration Number
- NCT00040755
- Locations
- 🇺🇸
UC Davis Comprehensive Cancer Center, Sacramento, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath